Introduction Methods
Ketoconazole is a new oral imidazole derivative which is active against both superficial and deep fungal infections. Its pharmacokinetics after oral dosing have been examined in normal subjects (Daneshmend et al., 1981 (Daneshmend et al., , 1983 Gascoigne et al., 1981; Mannisto et al., 1982) , in patients with different fungal infections (Brass et al., 1982; Gascoigne et al., 1981) and in immunocompromised patients (Hann etal., 1982; Maksymiuk et al., 1982) . In view of the dysmorphogenic effects of ketoconazole noted in animals (Heel et al., 1982) The poor vaginal absorption of ketoconazole may in part be due to the physicochemical properties of the drug. Ketoconazole is a weak dibasic compound (pKal = 6.51; pKa2 = 2.94) and is almost insoluble in water except at a pH lower than 3. Thus the normal vaginal pH of about 4.5 would tend to hinder the solubility and absorption of ketoconazole. The possibility exists of greater amounts of ketoconazole being absorbed in the presence of vaginal candidiasis, if this infection were to significantly lower vaginal pH. The AUC and half-life after oral administration seen in this study are similar to those observed by us in other studies in normal subjects (Daneshmend et al., 1981 (Daneshmend et al., , 1983 . The plasma ketoconazole concentrations after both oral and vaginal administration were extremely low after 24 h and decreased still further by 48 h. The data after vaginal administration did not allow calculation of half-life. The delay of4 to 6 h in reaching peak plasma concentrations after vaginal doses suggested slow dissolution and gradual systemic absorption of small amounts of ketoconazole.
In pregnant rats, high doses of ketoconazole (80 and 160 mg ketoconazole/100 mg of food) have resulted in dysmorphogenic effects in pups (Heel et al., 1982) . In addition, tritiated ketoconazole when given to pregnant rats leads to radioactivity in the placenta, but foetal tissue levels were much lower than maternal tissue levels (Heel et al., 1982) . However, the present study shows that less than 1% of the vaginal dose disperses into the systemic circulation in healthy adult females. Therefore most of the drug would be present in the vagina for the treatment of local fungal infections such as vaginal candidiasis. If clinical trials show ketoconazole pessaries to be effective in such infections, then vaginal administration may be safer than oral administration in pregnancy.
